Relevant bibliographies by topics / Tumour active

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Tumour active'

Author: Grafiati
Published: 4 June 2021
Last updated: 20 February 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Tumour active.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Tumour active"

1

Keln, A. A., S. S. Schmidt, A. V. Kupchin, and B. A. Berdichevsky. "Active monitoring of contrast-accumulating kidney tumours." Urology Herald 8, no. 4 (December 23, 2020): 53–61. http://dx.doi.org/10.21886/2308-6424-2020-8-4-53-61.

Full text
Abstract:
Introduction. The incidence of kidney cancer (KC) in the world is increasing and today is about 3%, but the death rate from this type of malignancy does not increase proportionally. According to research by many authors, more than half of the patients are over 65 years old at the time of diagnosis. Patients at this age have a high incidence of high comorbidity and risk of death from cardiovascular or other intercurrent pathology that exceeds the risk of death from KC. Recently, there has been a positive trend in the detection of the disease in the early stages up to 61.80%. Most of the primary detected kidney tumours are diagnosed randomly as asymptomatically small (less than 4 cm) tumours without signs of visceral metastasis. These tumours have a high degree of differentiation and rarely require surgical treatment in addition to their small size, and in the case of surgery, these pathomorphological results are benign. Due to the slow progredient growth of kidney formations and an asymptomatic course, the method of dynamic observation of kidney tumours is relevant in elderly patients and avoids unnecessary risks of surgical treatment of localized KC.Purpose of the study. To trace the growth rate of kidney tumours accumulating contrast agent using the method of dynamic observation. This study will allow us to differentially approach the choice of surgical treatment, which is optimal for elderly patients with low somatic status.Materials and methods. In the Multidisciplinary clinical medical centre «Medical City» (Tyumen) database all cases of radiographically verified space-occupying lesions of the kidneys that accumulate contrast were selected in the period from 2009 to 2019. We studied 50 people: 23 women (46%) and 27 men (54%), aged from 58 to 90 years. The study group included patients with kidney neoplasms of size < 7cm. Patients whose follow-up period was less than 12 months were excluded from the analysis. Regularly, every 3 to 6 months, patients underwent computed tomography to assess the growth dynamics. The size of the tumour, which was assumed to be its diameter in the largest dimension, was carefully studied. The growth rate of the tumour was calculated as the average change in diameter for 1 year during the entire observation period.Results. The average age of patients was 74.8 ± 7.4 years according to the results of the study. The age of patients at the time of diagnosis also had no prognostic significance for the rate of growth of kidney tumours (p > 0.05). The primary diagnosis was made in 32 patients (64%) using CT, in 18 (36%) using ultrasound. The average size of the tumou at the time of detection was 35.0 ± 6.9 mm. Percutaneous kidney biopsy was performed in 2 patients for morphological verification of the tumour type. Moderate-differentiated light-cell renal cell carcinoma pT1bN0M0 was detected in both patients according to the results of histological differentiation. The average linear growth rate of the tumour was 6.6 ± 2.4 mm / year. The size of the tumour at the time of diagnosis was not correlated with the growth rate (p > 0.05). There was no correlation between the rate of increase in the size of formations depending on their structure — solid (median 6 mm / year; average — 10 mm / year) or cystic-solid (median 7 mm / year; average 9 mm / year; p > 0.05). The absence of tumour growth dynamics during the entire observation period was detected in 22 (44%) people, including 10 (20%) men and 12 (24%) women. Visceral metastasis was diagnosed in 3 cases: to the liver, spleen, and the appearance of a second tumour on the contralateral kidney. Surgical treatment was performed in 4 patients (8%), in 2 (4%) cases, the indication for surgery was the progression of the tumour in the form of the appearance of visceral metastases. One patient had chromophobic KC pT1bN0M1, the other had renal cell carcinoma, a light-cell variant of pT1bN0M1. The operation in the volume of kidney resection was performed in 2 (4%) patients, in both cases, morphologically confirmed renal cell carcinoma, light-cell variant pT1aN0M0. The presence of a cystic-solid component and the initial size of the tumour were potential radiographic signs that could predict the dynamics of an increase in renal parenchyma neoplasm.Conclusion. The tactic of actively observing the growth rates of kidney tumours that accumulate contrast material allowed us to better understand the biological behaviour of KC. It was found that most kidney malignancies have a slow growth rate when determining the linear growth rate of the tumour. This conclusion allows us to differentially approach the choice of surgical treatment, which is optimal for elderly patients with low somatic status. Because prognostic signs of KC have not yet been identified and are not fixed in international treatment protocols, all patients who are suitable candidates for surgery are shown operative treatment.
APA, Harvard, Vancouver, ISO, and other styles
2

&NA;. "Tumour-specific superantigens - super active." Inpharma Weekly &NA;, no. 896 (July 1993): 12. http://dx.doi.org/10.2165/00128413-199308960-00026.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sagnella, Sharon M., Joshua A. McCarroll, and Maria Kavallaris. "Drug delivery: Beyond active tumour targeting." Nanomedicine: Nanotechnology, Biology and Medicine 10, no. 6 (August 2014): 1131–37. http://dx.doi.org/10.1016/j.nano.2014.04.012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Bucella, Dario, Jean-Frédéric Limbosch, Frédéric Buxant, Philippe Simon, Isabelle Fayt, Vincent Anaf, and Jean-Christophe Noël. "Recurrence of Mitotically Active Cellular Fibroma of the Ovary." Obstetrics and Gynecology International 2009 (2009): 1–3. http://dx.doi.org/10.1155/2009/803062.

Full text
Abstract:
Background. 10% of ovarian fibromatous tumours typically exhibit increased cellularity, mitotic activity, and less frequently nuclear atypia. Therefore, the classification within the group of fibromatous tumours may represent some difficulties, thus, one or several of these features should appear.Case. We introduce the clinical and pathologic features based on one case of recurrence of a mitotically active cellular ovarian fibroma (MACF) in the pararectal fossa. This recurrence took place six years after primary surgery. Macroscopically, the tumour was firm, fibrous, well delimited, yellow-white without gross necrosis. On microscopic examination, it was composed of a densely cellular proliferation of fibrolastic-like cells with bland nuclear features and arranged in a fascicular pattern. There was no sign of significant atypia or necrosis.Conclusion. Recently, this case is the first report of a recurrence of MACF, following primary surgery with no tumoral rupture or surgical difficulty. The clinical outcome of ovarian cellular fibromas (CFs) and MACFs is typically uneventful. This case, however, strongly suggests maintaining a long-term clinical follow-up even though the principal tumour was surgically treated without tumour rupture or in the absence of adherence or any surgical difficulty.
APA, Harvard, Vancouver, ISO, and other styles
5

Shankar Dey, Bhabani, Manas Kumar Bera, and Binoy Krishna Roy. "Nonlinear active control of a cancerous tumour." International Journal of Engineering & Technology 7, no. 2.21 (April 20, 2018): 72. http://dx.doi.org/10.14419/ijet.v7i2.21.11839.

Full text
Abstract:
This paper deals with the control of a cancerous tumour growth. The model used is a Three-Dimensional Cancer Model (TDCM). The competition terms include tumour cells, healthy cells, and immune cells. Nature of the competition among the populations of tumour cells, healthy host cells, and immune cells results in a chaotic behaviour. In this paper, a nonlinear active control has been used to control the growth of a tumour. Effect of chemotherapy drug on the different cell populations has been studied. Our control objective is to control the tumour growth and minimize its population to a small value which can be considered as harmless.Along with the above objective, the normal cell population is also be maintained at a particular level. This work has been done completely inin-sillico environment. The simulation results are shown extensively to support the theoretical analysis and confirmed that the preliminary objectives of the paper are attained.
APA, Harvard, Vancouver, ISO, and other styles
6

Hirsjarvi, Samuli, Catherine Passirani, and Jean-Pierre Benoit. "Passive and Active Tumour Targeting with Nanocarriers." Current Drug Discovery Technologies 8, no. 3 (September 1, 2011): 188–96. http://dx.doi.org/10.2174/157016311796798991.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Salmaso, Stefano, Sara Bersani, Alessandra Semenzato, and Paolo Caliceti. "New cyclodextrin bioconjugates for active tumour targeting." Journal of Drug Targeting 15, no. 6 (January 2007): 379–90. http://dx.doi.org/10.1080/10611860701349752.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Yan, Hengkang, Mary E. Vail, Linda Hii, Nancy Guo, Paul J. McMurrick, Karen Oliva, Simon Wilkins, et al. "Preferential Antibody and Drug Conjugate Targeting of the ADAM10 Metalloprotease in Tumours." Cancers 14, no. 13 (June 28, 2022): 3171. http://dx.doi.org/10.3390/cancers14133171.

Full text
Abstract:
ADAM10 is a transmembrane metalloprotease that sheds a variety of cell surface proteins, including receptors and ligands that regulate a range of developmental processes which re-emerge during tumour development. While ADAM10 is ubiquitously expressed, its activity is normally tightly regulated, but becomes deregulated in tumours. We previously reported the generation of a monoclonal antibody, 8C7, which preferentially recognises an active form of ADAM10 in human and mouse tumours. We now report our investigation of the mechanism of this specificity, and the preferential targeting of 8C7 to human tumour cell xenografts in mice. We also report the development of novel 8C7 antibody–drug conjugates that preferentially kill cells displaying the 8C7 epitope, and that can inhibit tumour growth in mice. This study provides the first demonstration that antibody–drug conjugates targeting an active conformer of ADAM10, a widely expressed transmembrane metalloprotease, enable tumour-selective targeting and inhibition.
APA, Harvard, Vancouver, ISO, and other styles
9

O'Rourke, N. P., E. V. McCloskey, and J. A. Kanis. "Tumour induced hypercalcaemia: A case for active treatment." Clinical Oncology 6, no. 3 (January 1994): 172–76. http://dx.doi.org/10.1016/s0936-6555(94)80057-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Herrmann, Th. "Radiation oncology and functional imaging." Nuklearmedizin 44, S 01 (2005): S38—S40. http://dx.doi.org/10.1055/s-0038-1625213.

Full text
Abstract:
Summary:PET/CT imaging is most likely to be of use in radiation oncology with patients who have poorly defined target volume areas, e.g. brain tumours, bronchogenic carcinoma, and cases of miscellaneous geographical miss. Other tumours that call for dose escalated radiotherapy, such as head and neck tumours, bronchogenic carcinoma, and prostate carcinomas may further benefit from an accurate delineation of the metabolically active tumour volume and its differentiation from surrounding healthy tissue, or tumour atelectasis.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Tumour active"

1

Daghriri, Hassan. "Studies on Tumour Active Compounds with Multiple Metal Centres." University of Sydney. Biomedical Sciences, 2004. http://hdl.handle.net/2123/595.

Full text
Abstract:
Four tumour active trinuclear complexes: DH4Cl: [{trans-PtCl(NH3)2}2m-{trans-Pd( NH3)2(H2N(CH2)4NH2)2]Cl4, DH5Cl: [{trans-PtCl(NH3)2}2m-{trans-Pd( NH3)2(H2N(CH2)5NH2)2]Cl4, DH6Cl: [{trans-PtCl(NH3)2}2m-{trans-Pd( NH3)2(H2N(CH2)6NH2)2]Cl4, DH7Cl: [{trans-PtCl(NH3)2}2m-{trans-Pd(NH3)2-( H2N(CH2)7NH2)2]Cl4 and one dinuclear complex DHD: [{trans-PtCl(NH3)2}�-{ H2N(CH2)6NH2}{trans-PdCl(NH3)2]Cl(NO3), have been prepared and characterised based on elemental analyses, IR, Raman, mass and 1 H NMR spectral measurements. For the trinuclear complexes, the synthesis has been carried out using a step-up method branching out from the central palladium unit. A purity of about 95% has been obtained by repeated dissolution and precipitation. The activity against human cancer cell lines including ovary cell lines: A2780, A2780 cisR , A2780 ZD0473R , non small lung cell line: NCI-H640 and melanoma: Me-10538 have been determined based on MMT assay. Cell uptakes, DNA-binding have been determined for ovary cell lines: A2780, A2780 cisR . The nature of interaction with pBR322 plasmid DNA and ssDNA has been studied for trinuclear complexes DH4Cl, DH5Cl, DH6Cl and DH7Cl and the dinuclear complex DHD. Interaction of DH6Cl with adenine and guanine has also been studied by HPLC. The compounds are found to exhibit significant anticancer activity against cancer cell lines especially ovarian cancer cell lines: A2780, A2780 cisR and A2780 ZD0473R . DH6Cl in which the linking diamine has six carbon atoms is found to be the most active compound. As the number of carbon atoms in thelinking diamine is changed from the optimum value of six, the activity is found to decrease, illustrating the structure-activity relationship. The increase in uptake of the trinuclear complexes in A2780 cell line with the increase in size of the linking diamine coupled with the low molar conductivity values found for the solutions of the compounds suggest that the compounds would remain in solution as undissociated �molecules� and hence could cross the cell membrane by passive diffusion. Much lower resistance factors for the all the multinuclear compounds including DHD as applied to A2780 cisR cell line, as compared to that for cisplatin, suggest that the compounds are able to overcome multiple mechanisms of resistance operating in the cell line. All of the multinuclear complexes are expected to form long-range interstrand GG adducts with DNA, causing irreversible global changes in the DNA conformation but unlike cisplatin do not cause sufficient DNA bending to be recognized by HMG 1 protein. Increasing prevention of BamH1 digestion with the increase in concentration of the multinuclear compounds also provide support to the idea that the compounds because of the formation of a plethora of interstrand GG adducts are able to cause irreversible changes in DNA conformation. The results of the study show that indeed new trinuclear tumour active compounds can be found by replacing the central platinum unit in BBR3464 with other suitable metal units.
APA, Harvard, Vancouver, ISO, and other styles
2

Daghriri, Hassan. "Studies on Tumour Active Compounds with Multiple Metal Centres." Thesis, The University of Sydney, 2003. http://hdl.handle.net/2123/595.

Full text
Abstract:
Four tumour active trinuclear complexes: DH4Cl: [{trans-PtCl(NH3)2}2m-{trans-Pd( NH3)2(H2N(CH2)4NH2)2]Cl4, DH5Cl: [{trans-PtCl(NH3)2}2m-{trans-Pd( NH3)2(H2N(CH2)5NH2)2]Cl4, DH6Cl: [{trans-PtCl(NH3)2}2m-{trans-Pd( NH3)2(H2N(CH2)6NH2)2]Cl4, DH7Cl: [{trans-PtCl(NH3)2}2m-{trans-Pd(NH3)2-( H2N(CH2)7NH2)2]Cl4 and one dinuclear complex DHD: [{trans-PtCl(NH3)2}�-{ H2N(CH2)6NH2}{trans-PdCl(NH3)2]Cl(NO3), have been prepared and characterised based on elemental analyses, IR, Raman, mass and 1 H NMR spectral measurements. For the trinuclear complexes, the synthesis has been carried out using a step-up method branching out from the central palladium unit. A purity of about 95% has been obtained by repeated dissolution and precipitation. The activity against human cancer cell lines including ovary cell lines: A2780, A2780 cisR , A2780 ZD0473R , non small lung cell line: NCI-H640 and melanoma: Me-10538 have been determined based on MMT assay. Cell uptakes, DNA-binding have been determined for ovary cell lines: A2780, A2780 cisR . The nature of interaction with pBR322 plasmid DNA and ssDNA has been studied for trinuclear complexes DH4Cl, DH5Cl, DH6Cl and DH7Cl and the dinuclear complex DHD. Interaction of DH6Cl with adenine and guanine has also been studied by HPLC. The compounds are found to exhibit significant anticancer activity against cancer cell lines especially ovarian cancer cell lines: A2780, A2780 cisR and A2780 ZD0473R . DH6Cl in which the linking diamine has six carbon atoms is found to be the most active compound. As the number of carbon atoms in thelinking diamine is changed from the optimum value of six, the activity is found to decrease, illustrating the structure-activity relationship. The increase in uptake of the trinuclear complexes in A2780 cell line with the increase in size of the linking diamine coupled with the low molar conductivity values found for the solutions of the compounds suggest that the compounds would remain in solution as undissociated �molecules� and hence could cross the cell membrane by passive diffusion. Much lower resistance factors for the all the multinuclear compounds including DHD as applied to A2780 cisR cell line, as compared to that for cisplatin, suggest that the compounds are able to overcome multiple mechanisms of resistance operating in the cell line. All of the multinuclear complexes are expected to form long-range interstrand GG adducts with DNA, causing irreversible global changes in the DNA conformation but unlike cisplatin do not cause sufficient DNA bending to be recognized by HMG 1 protein. Increasing prevention of BamH1 digestion with the increase in concentration of the multinuclear compounds also provide support to the idea that the compounds because of the formation of a plethora of interstrand GG adducts are able to cause irreversible changes in DNA conformation. The results of the study show that indeed new trinuclear tumour active compounds can be found by replacing the central platinum unit in BBR3464 with other suitable metal units.
APA, Harvard, Vancouver, ISO, and other styles
3

Tayyem, Hasan. "Studies on new tumour active compounds with one or more metal centres." zConnect to full text, 2006. http://hdl.handle.net/2123/1727.

Full text
Abstract:
Thesis (Ph. D.)--University of Sydney, 2007.
Title from title screen (viewed may 17, 2007). Submitted in fulfilment of the requirements for the degree of Doctor of Philosophy to the School of Biomedical Sciences, Faculty of Health Sciences. Degree awarded 2007; thesis submitted 2006. Includes bibliographical references. Also issued in print.
APA, Harvard, Vancouver, ISO, and other styles
4

Tayyem, Hasan Mohammad. "Studies on new tumour active compounds with one or more metal centres." Thesis, The University of Sydney, 2006. http://hdl.handle.net/2123/1727.

Full text
Abstract:
The present study deals with the synthesis, characterization, determination of anticancer activity of three mononuclear trans-planaraminepalladium(II) complexes code named TH5, TH6 and TH7 and three trinuclear complexes code named TH1, TH8 and TH14. The activity of the compounds against human cancer cell lines: A2780, A2780cisR and A2780ZD0473R, cell uptake, DNA-binding and nature of interaction with pBR322 plasmid DNA have been determined. Whereas cisplatin binds with DNA forming mainly intrastrand GG adduct that causes local bending of a DNA strand, TH5, TH6, TH7, TH1 and TH8 bind with DNA forming mainly interstrand GG adducts that causes more of a global change in DNA conformation. Although TH5, TH6 and TH7 each have two substituted pyridine ligands in a trans-geometry (3-hydroxypyridine in TH5, 2-hydroxypyridine in TH6 and 4-hydroxypyridine in TH7), the compounds differ in their activity against ovarian cancer cell lines, indicating that non-covalent interactions involving the hydroxyl group may be playing a significant role in activity of the compounds. Among trinuclear complexes TH1 is found to be significantly more active than cisplatin. It is actually twice as active as cisplatin against the parent cell line A2780, thirteen times as active as cisplatin against the cisplatin-resistant cell line A2780cisR and 11.5 times as active as cisplatin against the cell line A2780ZD0473R. Whereas the resistance factor for cisplatin as applied to the cell lines A2780 and A2780cisR cell lines is 12.9 that for TH1 is 1.98. The results suggest that TH1 has been able to significantly overcome resistance operating in A2780cisR cell line. The compound is soluble in water so that it may be taken orally. Provided it has favourable toxicity profile, TH1 has the potential to be developed into a highly active anticancer drug with a wider spectrum of activity than cisplatin. Although platinum drugs use a shot-gun approach to kill cancerous cells, widespread use in the clinic and increasing volume of their sale indicate that even in the genomic age, there is still need for shot-gun drugs in the clinic.
APA, Harvard, Vancouver, ISO, and other styles
5

Tayyem, Hasan Mohammad. "Studies on new tumour active compounds with one or more metal centres." Faculty of Health Sciences, 2006. http://hdl.handle.net/2123/1727.

Full text
Abstract:
Doctor of Philosophy(PhD)
The present study deals with the synthesis, characterization, determination of anticancer activity of three mononuclear trans-planaraminepalladium(II) complexes code named TH5, TH6 and TH7 and three trinuclear complexes code named TH1, TH8 and TH14. The activity of the compounds against human cancer cell lines: A2780, A2780cisR and A2780ZD0473R, cell uptake, DNA-binding and nature of interaction with pBR322 plasmid DNA have been determined. Whereas cisplatin binds with DNA forming mainly intrastrand GG adduct that causes local bending of a DNA strand, TH5, TH6, TH7, TH1 and TH8 bind with DNA forming mainly interstrand GG adducts that causes more of a global change in DNA conformation. Although TH5, TH6 and TH7 each have two substituted pyridine ligands in a trans-geometry (3-hydroxypyridine in TH5, 2-hydroxypyridine in TH6 and 4-hydroxypyridine in TH7), the compounds differ in their activity against ovarian cancer cell lines, indicating that non-covalent interactions involving the hydroxyl group may be playing a significant role in activity of the compounds. Among trinuclear complexes TH1 is found to be significantly more active than cisplatin. It is actually twice as active as cisplatin against the parent cell line A2780, thirteen times as active as cisplatin against the cisplatin-resistant cell line A2780cisR and 11.5 times as active as cisplatin against the cell line A2780ZD0473R. Whereas the resistance factor for cisplatin as applied to the cell lines A2780 and A2780cisR cell lines is 12.9 that for TH1 is 1.98. The results suggest that TH1 has been able to significantly overcome resistance operating in A2780cisR cell line. The compound is soluble in water so that it may be taken orally. Provided it has favourable toxicity profile, TH1 has the potential to be developed into a highly active anticancer drug with a wider spectrum of activity than cisplatin. Although platinum drugs use a shot-gun approach to kill cancerous cells, widespread use in the clinic and increasing volume of their sale indicate that even in the genomic age, there is still need for shot-gun drugs in the clinic.
APA, Harvard, Vancouver, ISO, and other styles
6

Subbotina, Beztsinna Nataliia. "Riboflavin-based amphiphiles for tumour-targeted nanosystems." Thesis, Bordeaux, 2015. http://www.theses.fr/2015BORD0254/document.

Full text
Abstract:
La riboflavine (RF) est une vitamine essentielle pour la croissance et le développement cellulaire. Elle possède des propriétés physico-chimiques intéressantes et est internalisée dans les cellules par des transporteurs spécifiques. Le premier objectif de ce projet était de synthétiser des dérivés amphiphiles de la RF (RFA) et d'étudier leurs capacités d'auto-assemblages. Le second objectif était d'insérer les RFA dans des liposomes et d'évaluer leur efficacité de ciblage tumoral in vitro et in vivo. La préparation des différents RFA repose sur l'ajout d'un lipide en différentes positions de la RF. L’un d'eux, de type phospholipide (RfdiC14) a été capable de former des objets tridimensionnels de taille μm constitués de lamelles multicouches dont l’architecture et la dynamique sont très différentes de celles des phospholipides classiques. L’insertion de RfdiC14 dans des liposomes est efficace et n’influence pas leurs propriétés physico-chimiques. Les liposomes fonctionnalisés ont montré une internalisation cellulaire spécifique dans les lignées A431, PC3 et HUVECs. Afin de tester l’efficacité du ciblage tumoral in vivo, un analogue de RfdiC14 portant un espaceur PEG a été préparé puis inséré dans des liposomes péguylés. Grâce à un marquage adéquat (ICG et DiR), leur accumulation tumorale a été suivie par imagerie photoacoustique dans un modèle A431 et leur biodistribution évaluée par imagerie μCT/FMT dans un modèle PC3. Les résultats montrent une légère amélioration de l’accumulation tumorale dans les xénogreffes A431 et une augmentation du ciblage vasculaire dans le modèle tumoral PC3. La biodistribution globale des liposomes marqués est comparable à celle des contrôles
Riboflavin (RF) is an essential vitamin for cell growth and development. It possesses interesting physicochemical properties and is internalized by the cells through specific transporters. The first aim of this study was to prepare amphiphile derivatives of RF (RFA) and study their auto-assembly. The second aim was to insert RFA into established drug delivery systems and test their tumour-targeting potential in vitro and in vivo. RFA were prepared by the molecule functionalization with lipid moieties in different positions. One of them, a phospholipid-like derivative (RfdiC14) was able to self-assembly in aqueous solutions into μm-sized 3D objects constituted from slightly curved multilayer lamellas. The bilayer architecture and dynamics were very different from ordinary phospholipids. In contrast, the insertion of small amount of RfdiC14 in a liposome did not influence membrane dynamics and physicochemical characteristics. RfdiC14-functionalised liposomes displayed high and specific uptake in vitro in A431, PC3 cells and HUVECs. The efficiency of RF targeting was also tested in vivo. For that purpose, liposome composition was optimized and a new RF amphiphile with a PEG spacer between RF and lipid was prepared. The tumour accumulation of the liposomes labelled with ICG was studied by photoacoustic imaging in A431 tumour model. The biodistribution of DiR labelled liposomes was accessed by combined μCT/FMT imaging in PC3 tumour model. The results show slight improvement of the tumour accumulation in A431 xenographts and the enhancement of vascular targeting in PC3 tumour model. The overall biodistribution of the RF-targeted liposomes was comparable to control
APA, Harvard, Vancouver, ISO, and other styles
7

Lavaud, Mélanie. "Identification des acteurs clés impliqués dans le développement du tissu osseux et l'évolution des ostéosarcomes par études des super-enhancers actifs." Thesis, Nantes Université, 2022. http://www.theses.fr/2022NANU1019.

Full text
Abstract:
Les super-enhancers (SE) correspondent à des groupement d'enhancers qui recrutent le complexe transcriptionnel pour induire la transcription de leurs gènes cibles plus efficacement que les enhancers. Ils régulent des gènes clés définissant l'identité cellulaire dans des conditions physiologiques et pathologiques. Les objectifs de ce projet de thèse étaient de caractériser le développement osseux normal par l'étude des gènes clés de l'ostéoblastogenèse et de l'ostéoclastogenèse et de caractériser l'évolution métastatique de l'ostéosarcome (OS), la tumeur osseuse primitive maligne la plus fréquente. Nous avons traqué la reprogrammation épigénétique qui se produit au cours de l'ostéoclastogenèse, et associé les SEs actifs dynamiques à leurs gènes cibles potentiels. Ainsi, nous avons pu observer un profil dynamique d'enhancers actifs qui stimule la transcription de gènes clés définissant l'identité des ostéoclastes. L'expression de ces gènes semble être particulièrement affectée par l'exposition au diuron, pesticide suspecté de provoquer des troubles du développement squelettique, altérant la maturation des ostéoclastes. Afin d'identifier les facteurs de transcription (TFs) impliqués dans l'ostéoblastogenèse, nous avons traqué les gènes codant pour des TFs induits par des SEs actifs spécifiques de l'état de différenciation dans un modèle in vitro de différenciation ostéoblastique de cellules souches mésenchymateuses (CSMs). Un ChIP-Sequencing contre la marque H3K27ac des enhancers actifs a été réalisé sur des cellules traitées et non traitées avec du milieu de différenciation à différents temps, ainsi qu'un RNA-Sequencing aux mêmes temps. Nous avons identifié 3 TFs, clés pour l'ostéoblastogenèse, comme cibles de SEs actifs spécifiques du stade de différenciation tardif et un TF induit par un SE spécifique aux CSMs. Les modifications de l'expression de ces TFs liées aux SEs peuvent être des stratégies prometteuses pour lutter contre divers troubles du tissu osseux. En parallèle, nous avons comparé les profils des SEs actifs dans différentes lignées cellulaires d’OS et dans des échantillons tumoraux extraits de sites primaires et métastatiques. Le regroupement hiérarchique des profils de SEs actifs nous a permis de distinguer deux ensembles d'échantillons d’OS : un groupe contenant les échantillons primaires et la lignée cellulaire MG63 et un second groupe contenant les échantillons métastatiques et les lignées cellulaires U2OS et HOS-MNNG. Nous avons identifié 3 gènes qui sont induits par des SEs actifs spécifiques aux métastases. Les sous expressions simultanées des 3 gènes identifiés diminuent les capacités d'infiltration et de motilité des HOS-MNNG et donc leur capacité métastatique. Le suivi des gènes cibles des profils évolutifs des SEs actifs pourrait par conséquent être utilisé pour l'identification des gènes qui gouvernent la différenciation cellulaire et façonnent le comportement cellulaire, qu'il soit physiologique ou pathologique
Super-enhancers (SEs) are cluster of enhancers that recruit the transcriptional complex to induce the transcription of their target genes more efficiently than enhancers. They regulate key cell identity defining genes in physiological and pathological conditions. The objectives of this thesis project were to characterize normal bone development through the study of osteoblastogenesis and osteoclastogenesis driver genes and to characterize the metastatic evolution of osteosarcoma (OS), the most frequent malignant primary bone tumour. We tracked the epigenetic reprogramming occurring during osteoclastogenesis, and associated dynamic active SEs to their potential target genes. As such, we were able to observe a dynamic active enhancers profile that boosts transcription of key osteoclasts identity defining genes. The expression of these genes seemed to be particularly affected by diuron exposure, pesticide suspected to cause skeletal disorders, impairing osteoclasts maturation. In order to identify transcription factors (TFs) involved in osteoblastogenesis, we tracked TF-encoding genes induced by differentiation state specific active SEs in an in vitro model of mesenchymal stem cells (MSCs) osteoblastic differentiation. ChIP-Sequencing for the active enhancers marker H3K27ac was performed in differentiation medium treated and untreated cells at different time points along with RNA-Sequencing at the same time points. We identified 3 TFs, key for osteoblastogenesis, as targets of late stage differentiation specific active SEs and one MSCs specific SE induced TF. Expression modifications of these SEs related TFs may be promising strategies to fight against various bone disorders. In parallel, we compared the active SEs profiles in different OS cell lines and tumor samples extracted from primary and metastatic sites. Hierarchical clustering on the active SEs profiles allowed us to distinguish two sets of OS samples: one group containing the primary samples and MG63 cell line and the other containing metastatic samples with U2OS et HOS-MNNG cell lines. We identified 3 genes that are induced by metastasis specific active SEs. Simultaneous down expressions of the 3 identified genes decrease HOS-MNNG infiltration and motility capacities and thus their metastatic capacity. Tracking target genes of the evolving active SEs profiles could as a result be used for the identification of genes that drive cell differentiation and shape cellular behavior, whether physiological or pathological
APA, Harvard, Vancouver, ISO, and other styles
8

Milbank, Edward. "Extracellular vesicles as a therapeutic strategy to prevent or reverse obesity and its metabolic complications in the field of nanomedicine Extracellular vesicles: Pharmacological modulators of the peripheral and central signals governing obesity Microparticles from apoptotic RAW 264.7 macrophage cells carry tumour necrosis factor-a functionally active on cardiomyocytes from adult mice." Thesis, Angers, 2016. http://www.theses.fr/2016ANGE0074.

Full text
Abstract:
A ce jour, les thérapies anti-obésité restent limitées. De récente études ont fourni des résultats prometteurs en démontrant une diminution du poids de la souris via une injection stéréotaxique d’une forme dominante négative de l’AMPK (AMPK DN) directement dans le noyau ventromédial hypothalamique (VMH). Cependant, le potentiel thérapeutique de cette thérapie génique se voit entravé par une libération non spécifique de l’AMPK suite à une injection intraveineuse, plus adaptée à une approche clinique. Nous avons donc développé une approche de « nanobiomédecine » en utilisant des exosomes - nanovésicules contenant des lipides, des protéines et des acides nucléiques - pour délivrer l’AMPK DN spécifiquement au niveau du VMH. Des cellules dendritiques immatures ont été utilisées pour produire des exosomes non-inflammatoires. Pour permettre le ciblage spécifique du VMH par les exosomes, les cellules dendritiques ont été transfectées pour exprimer Lamp2b, une protéine exosomale, fusionnée au peptide de ciblage neuronal RVG. De façon intéressante, les exosomes Lamp2b-RVG ont été localisés au niveau du cerveau suite à une injection intraveineuse. Les exosomes Lamp2b-RVG ont ensuite été chargés par l’AMPK DN sous le contrôle d’un promoteur spécifique du VMH, apportant une double spéficité tissulaire aux exosomes. Les exosomes Lamp2b-RVG chargés avec l’AMPK DN induisaient une diminution de la phosphorylation de l’acetyl-CoA carboxylase dans des cellules Neu2A in vitro. De plus, l’injection intraveineuse d’exosomes Lamp2b-RVG chargés avec l’AMPK DN induisait une perte de poids de l’animal après 6 jours de traitement, démontrant le potentiel de cette approche de « nanobiomédecine »
Actual pharmacological therapies for treating obesity are limited. Promising results on decreasing mice body weight were obtained using a ventromedial nucleus hypothalamic (VMH) stereotaxic injection of a dominant negative isoform of AMPK (AMPK DN). However, DNA-mediated therapeutic potential is hampered by inadequate tissue specific delivery following a systemic injection - more adapted to a bedside approach -. Herein, we developed a nanobiomedicine approach using exosomes - nano-scaled endogenous vesicles containing lipids, proteins and nucleic acids - to deliver DNA in a hypothalamic specific way. Immature dendritic cells were used to generate non inflammatory exosomes. Exosome neuronal targeting aptitudes were achieved by constraining the dendritic cells to express Lamp2b, an exosomal protein, fused to the neuron-specific RVG peptide. Interestingly, DID-labelled Lamp2b-RVG exosomes were found into the mice brain following an intravenous injection. Isolated Lamp2b-RVG exosomes were then loaded by transfection-mediated techniques with AMPK DN under the control of a VMH specific promoter conferring double tissue expression specificity to the exosomes. AMPK DN-loaded exosomes induced a decrease of acetyl-CoA carboxylase phosphorylation in Neu2a neuronal cells in vitro. Furthermore, intravenously injected AMPK DN loaded exosomes induced a decrease of mice body weight following 6 days of treatment, demonstrating the potential of this nanobiomedicine approach
APA, Harvard, Vancouver, ISO, and other styles
9

Barbara, Jeffrey A. J. "The mechanism of action of tumour necrosis factor-[alpha] /." Title page, contents and abstract only, 1995. http://web4.library.adelaide.edu.au/theses/09PH/09phb229.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Roelofs, Anke. "Anti-tumour mechanisms of action bisphosphonates and bisphosphonate analogues." Thesis, University of Oxford, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.436994.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Tumour active"

1

Kushida, Michelle Mayumi. Identification of CIS-active targets of MHC class 1 transcritional downregulaton in tumour cells. Ottawa: National Library of Canada, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bates, P. I. Radiosynthesis and biological studies with platinum and carbon labelled JM216: An orally active platinum anti-tumour complex. Manchester: UMIST, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Orentas, Rimas. Cancer vaccines and tumor immunity. Hoboken, N.J: Wiley-Interscience, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

service), SpringerLink (Online, ed. Innate and Adaptive Immunity in the Tumor Microenvironment. Dordrecht: Springer Science + Business Media, LLC, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Ilgren, E. B. Mesotheliomas of animals: A comprehensive, tabular compendium of the world's literature. Boca Raton, Fla: CRC Press, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

1950-, Morstyn George, Foote MaryAnn, and Lieschke Graham J, eds. Hematopoietic growth factors in oncology: Basic science and clinical therapeutics. Totowa, N.J: Humana Press, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

C, Dale David, and SpringerLink (Online service), eds. Hematopoietic Growth Factors in Oncology. Boston, MA: Springer Science+Business Media, LLC, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Gen, Sobue, and New York Academy of Sciences, eds. Integrated molecular medicine for neuronal and neoplastic disorders. Boston: Blackwell Pub. on behalf of the New York Academy of Sciences, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Tamoxifen: Molecular basis of use in cancer treatment and prevention. Chichester: J. Wiley & Sons, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

L, Spitzer Hugh, ed. Receptor-mediated biological processess: Implications forevaluating carcinogenesis : proceedings of the Sixth International Conference on Carcinogenesis and Risk Assessment, held in Austin, Texas, on December 8-11, 1992. New York: Wiley-Liss, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Tumour active"

1

Gardiner, K. R., M. I. Halliday, F. Lloyd, S. Stephens, and B. J. Rowlands. "Circulating Tumour Necrosis Factor in Active Inflammatory Bowel Disease." In Host Defense Dysfunction in Trauma, Shock and Sepsis, 699–703. Berlin, Heidelberg: Springer Berlin Heidelberg, 1993. http://dx.doi.org/10.1007/978-3-642-77405-8_90.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Rotomskis, R. "Primary Photoprocesses in Biologically Active Pigments Related to Photosensitized Tumour Therapy." In Ultrafast Processes in Spectroscopy, 507–10. Boston, MA: Springer US, 1996. http://dx.doi.org/10.1007/978-1-4615-5897-2_113.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Burdon, R. H. "Cellularly generated active oxygen species as signals in the activation of tumour cell growth." In Oxidative Stress, Cell Activation and Viral Infection, 43–52. Basel: Birkhäuser Basel, 1994. http://dx.doi.org/10.1007/978-3-0348-7424-3_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Dietz, C., J. S. Becker, S. Hennig, V. Welter, I. Celik, and D. K. Bartsch. "Inhibition of the enzyme Dihydroorotate Dehydrogenase by Leflunomid and the active metabolite A 771726 inhibits in vitro tumour cell proliferation and in vivo tumour growth in pancreatic carcinoma SCID mouse model." In Deutsche Gesellschaft für Chirurgie, 51–53. Berlin, Heidelberg: Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-642-00625-8_21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Maraveyas, A., and A. G. Dalgleish. "Active Immunotherapy for Solid Tumours." In Vaccine Design, 129–46. Boston, MA: Springer US, 1997. http://dx.doi.org/10.1007/978-1-4899-0062-3_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Cerutti, Peter A. "Active Oxygen and Promotion." In Arachidonic Acid Metabolism and Tumor Promotion, 131–68. Boston, MA: Springer US, 1985. http://dx.doi.org/10.1007/978-1-4613-2605-2_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Leppien, G., G. Dallenbach-Hellweg, T. Rabe, and B. Runnebaum. "Hormonal Active Ovarian Tumors." In Gynecological Endocrinology and Reproductive Medicine, 321–40. Berlin, Heidelberg: Springer Berlin Heidelberg, 1997. http://dx.doi.org/10.1007/978-3-642-60390-7_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Patel, Hiten D., and Phillip M. Pierorazio. "Active Surveillance of Renal Tumors." In Diagnosis and Surgical Management of Renal Tumors, 101–13. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-92309-3_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Weber, Sharon M., and Fred T. Lee. "Cryoablation: History, Mechanism of Action, and Guidance Modalities." In Tumor Ablation, 250–65. New York, NY: Springer New York, 2005. http://dx.doi.org/10.1007/0-387-28674-8_20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Todaro, George J. "Tumor Growth Factors." In Molecular Basis of Lymphokine Action, 3–12. Totowa, NJ: Humana Press, 1987. http://dx.doi.org/10.1007/978-1-4612-4598-8_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Tumour active"

1

Vepřek, Pavel, Kateřina Knytlová, Miroslav Ledvina, Tomáš Trnka, and Jan Ježek. "The preparation of multivalent peptide and glycopeptide dendrimers bearing Tn tumour antigens." In VIIth Conference Biologically Active Peptides. Prague: Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, 2001. http://dx.doi.org/10.1135/css200104017.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kot, Estera, Zuzanna Krawczyk, Krzysztof Siwek, and Piotr S. Czwarnowski. "U-Net and Active Contour Methods for Brain Tumour Segmentation and Visualization." In 2020 International Joint Conference on Neural Networks (IJCNN). IEEE, 2020. http://dx.doi.org/10.1109/ijcnn48605.2020.9207572.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Zeng, Ziming, Jue Wang, Tony Shepherd, and Reyer Zwiggelaar. "Region-based active surface modelling and alpha matting for unsupervised tumour segmentation in PET." In 2012 19th IEEE International Conference on Image Processing (ICIP 2012). IEEE, 2012. http://dx.doi.org/10.1109/icip.2012.6467280.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ziming Zeng, T. Shepherd, and R. Zwiggelaar. "Unsupervised tumour segmentation in PET based on local and global intensity fitting active surface and alpha matting." In 2012 34th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC). IEEE, 2012. http://dx.doi.org/10.1109/embc.2012.6346432.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Boki, KA, VA Vassiliou, G. Linardaki, and HM Moutsopoulos. "FRI0060 Successful treatment of active rheumatoid arthritis with chimeric monoclonal antibody to tumour necrosis factor (infliximab): an open study." In Annual European Congress of Rheumatology, Annals of the rheumatic diseases ARD July 2001. BMJ Publishing Group Ltd and European League Against Rheumatism, 2001. http://dx.doi.org/10.1136/annrheumdis-2001.1189.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Coates, LC, P. Mease, ME Husni, E. Lespessailles, DH Adams, O. Benichou, L. Kerr, and P. Helliwell. "FRI0502 Ixekizumab reduces disease activity in active psoriatic arthritis patients who had previous inadequate response to tumour necrosis factor-inhibitors." In Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.2757.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kavanaugh, A., R. Vender, J. Birt, DH Adams, O. Benichou, C.-Y. Lin, and P. Nash. "SAT0446 Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and previous inadequate response to tumour necrosis factor-inhibitors." In Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.1580.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

"Descriptive Epidemiological Study of Colorectal Cancer Patients at a Tertiary Hospital in North Jordan." In International Conference on Public Health and Humanitarian Action. International Federation of Medical Students' Associations - Jordan, 2022. http://dx.doi.org/10.56950/wyzq8668.

Full text
Abstract:
Introduction and Aim Colorectal cancer (CRC) incidences have been steadily on the rise and is one of the common cancers worldwide; it accounted for 10.7% of all new cancer incidences in 2016 in Jordan. We aim to describe epidemiological, demographical, and clinical characteristics of CRC in North Jordan. Methods A single-center retrospective review of all patients diagnosed with CRC between 2003 and 2019 at King Abdullah University Hospital (KAUH) in Irbid, North of Jordan was performed. Clinical and demographical data were extracted from the patients’ medical records. Patients were stratified by age groups into younger (≤50) and older (>50), and by tumor location into right colon (cecum, ascending, transverse), left colon (descending, sigmoid), and rectum. Patients with multifocal tumors were excluded. Results 514 CRC cases were identified. Males constituted 55.8% of the patients. The median age upon diagnosis was 59 years (IQR 49-68). Stage 4 was the most frequent among our sample (157/454; 34.58%) with most patients having grade 2 tumors (397/472; 84.1%) and invasive adenocarcinoma subtype (421/514; 81.9%). Left colon was the most common location in both age groups, followed by the rectum in the younger group and the right colon for the older group. Regarding tumor sidedness, left-sided tumors were the most common (38.9%), followed by right-sided (32.3%) with sigmoid (64%) and ascending colon (40.4%) being the most affected anatomical locations within right-sided and left-sided tumors respectively. The right colon group had the highest proportion of high-grade cases (18.4%) when compared with the other two (P < 0.001). Significant associations between tumor location and mean age, tumor grade, histological subtype, smoking, HTN status, and having a positive family history were identified. Conclusion Patients in our cohort were more likely to have advanced stages of CRC upon diagnosis which emphasizes the importance of screening when there’s clinical suspicion.
APA, Harvard, Vancouver, ISO, and other styles
9

Merola, J. F., P. Rich, J. P. Dutz, D. Adams, L. Kerr, and L. E. Kristensen. "THU0313 Ixekizumab improves nail and skin lesions through 52 weeks in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.2347.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Nash, P., B. Kirkham, M. Okada, P. Rahman, B. Combe, DH Adams, LN Kerr, CH Lee, CL Shuler, and MC Genovese. "OP0201 A phase 3 study of the efficacy and safety of ixekizumab in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitor(s)." In Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.1576.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Tumour active"

1

Vazquez, Francisca. Regulation of the PTEN Tumor Suppressor: Identification of the Active Protein Complex. Fort Belvoir, VA: Defense Technical Information Center, April 2004. http://dx.doi.org/10.21236/ada429196.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Zacksenhaus, Eldad. Dominant-Active Alleles of Rb as Universal Tumor Suppressors of Mammary Carcinoma. Fort Belvoir, VA: Defense Technical Information Center, October 1999. http://dx.doi.org/10.21236/ada382540.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Zhan, Xi. The Role of Actin Polymerization in Tumor Metastasis. Fort Belvoir, VA: Defense Technical Information Center, August 2004. http://dx.doi.org/10.21236/ada431324.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Zhan, Xi. The Role of Actin Polymerization in Tumor Metastasis. Fort Belvoir, VA: Defense Technical Information Center, August 2002. http://dx.doi.org/10.21236/ada411545.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Zhan, Xi. The Role of Actin Polymerization in Tumor Metastasis. Fort Belvoir, VA: Defense Technical Information Center, August 2003. http://dx.doi.org/10.21236/ada420763.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Lee, Jiing-Dwan. Molecular Action of a Potential Tumor Suppression in Mammary Carcinogenesis. Fort Belvoir, VA: Defense Technical Information Center, May 2006. http://dx.doi.org/10.21236/ada456140.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Wang, Lizhong. Synergistic Action of FOXP3 and TSC1 Pathways During Tumor Progression. Fort Belvoir, VA: Defense Technical Information Center, October 2015. http://dx.doi.org/10.21236/ada625959.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Gail A. Bishop, Gail A. Bishop. Using Nanoparticles to Activate Immune Cells to Fight Tumors. Experiment, September 2014. http://dx.doi.org/10.18258/3518.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Inoue, Takashi, and Mamoru Narukawa. Anti-tumor efficacy of anti-PD-1/PD-L1 antibodies in combination with other anticancer drugs in solid tumors: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, October 2022. http://dx.doi.org/10.37766/inplasy2022.10.0004.

Full text
Abstract:
Review question / Objective: The aim of this systematic review is to compare the combination of PD-1/PD-L1 inhibitors plus other anticancer drugs and monotherapies of PD-1/PD-L1 inhibitors in terms of antitumor efficacy in the solid tumors to better inform clinical practice. To this end, the proposed systematic review will address the following question: Which is the best choice to enhance response rate in subjects with solid tumors, PD-1/PD-L1 inhibitors plus cytotoxic agents or PD-1/PD-L1 inhibitors plus other targeted anticancer drugs? Condition being studied: Cancer is the leading cause of death worldwide, accounting to approximately 9.6 million deaths worldwide in 2018. The clinical efficacy of immune checkpoint inhibitors (CPIs) including PD-1/PD-L1 inhibitors has been proven; however, it is also known that their efficacy as monotherapy is limited, with a response rate of 20% or less in solid tumors. The combination of CPIs and anticancer agents has been actively attempted in solid tumors area.
APA, Harvard, Vancouver, ISO, and other styles
10

Ramesh, Vijaya. Neurofibromatosis 2 Tumor Suppressor Protein, Merlin, in Cellular Signaling to Actin Cytoskeleton. Fort Belvoir, VA: Defense Technical Information Center, October 2000. http://dx.doi.org/10.21236/ada395581.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Tumour active' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography